Haemonetics (NYSE:HAE) Receives Hold (C-) Rating from Weiss Ratings

Haemonetics (NYSE:HAE)‘s stock had its “hold (c-)” rating reissued by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other research analysts have also weighed in on the company. Baird R W upgraded Haemonetics to a “strong-buy” rating in a report on Wednesday, June 25th. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and dropped their target price for the company from $105.00 to $78.00 in a report on Monday, August 11th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Mizuho dropped their target price on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Finally, Robert W. Baird initiated coverage on Haemonetics in a report on Thursday, June 26th. They issued an “outperform” rating and a $87.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $75.89.

Haemonetics Stock Up 3.5%

Shares of NYSE:HAE opened at $50.99 on Wednesday. The business’s 50 day simple moving average is $54.66 and its two-hundred day simple moving average is $63.38. The firm has a market cap of $2.46 billion, a P/E ratio of 15.59, a PEG ratio of 0.91 and a beta of 0.37. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. Haemonetics has a 52-week low of $47.31 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The company had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. During the same quarter last year, the company earned $1.02 earnings per share. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in HAE. SG Americas Securities LLC grew its position in shares of Haemonetics by 510.9% in the first quarter. SG Americas Securities LLC now owns 10,580 shares of the medical instruments supplier’s stock valued at $672,000 after purchasing an additional 8,848 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its position in shares of Haemonetics by 88.6% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 517,086 shares of the medical instruments supplier’s stock valued at $32,861,000 after purchasing an additional 242,956 shares in the last quarter. Cardinal Capital Management grew its position in shares of Haemonetics by 8.4% in the first quarter. Cardinal Capital Management now owns 19,815 shares of the medical instruments supplier’s stock valued at $1,259,000 after purchasing an additional 1,531 shares in the last quarter. Boston Trust Walden Corp grew its position in shares of Haemonetics by 22.1% in the first quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier’s stock valued at $71,070,000 after purchasing an additional 202,609 shares in the last quarter. Finally, Schwartz Investment Counsel Inc. grew its position in shares of Haemonetics by 148.0% in the first quarter. Schwartz Investment Counsel Inc. now owns 374,500 shares of the medical instruments supplier’s stock valued at $23,799,000 after purchasing an additional 223,500 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.